Atrasentan: Clinical Trials

12 trials of Atrasentan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 1 active not recruiting, 1 terminated. 12 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 212Completed 10, Active not recruiting 1, Terminated 1
Phase 31Completed 1

Follow Atrasentan: new trials by email Literature Review of Atrasentan trials Research Report on Atrasentan

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
Atrasentan, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy
Phase 2CompletedNovartis Pharmaceuticals542023-07-202026-07-20
Atrasentan in Patients With Proteinuric Glomerular Diseases
Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis
Phase 2Active not recruitingNovartis Pharmaceuticals1032021-03-152026-06-01
Atrasentan Spermatogenesis and Testicular Function
Atrasentan - Nephropathy, Diabetes
Phase 2CompletedAbbVie202015-04-062019-05-07
A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy
Atrasentan, Placebo - Chronic Kidney Disease, Diabetic Nephropathy
Phase 2CompletedAbbVie (prior sponsor, Abbott)482011-08-012013-10-25
Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan
Atrasentan low dose group, Atrasentan high dose group, Atrasentan placebo group - Chronic Kidney Disease, Diabetic Nephropathy
Phase 2CompletedAbbVie (prior sponsor, Abbott)582011-08-012017-08-29
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Atrasentan, Placebo - Chronic Kidney Disease, Diabetic Nephropathy
Phase 2CompletedAbbVie (prior sponsor, Abbott)1492011-04-012013-08-28
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
Placebo for Atrasentan 0.2 mg/mL solution, 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD - Chronic Kidney Disease, Diabetic Nephropathy
Phase 2CompletedAbbVie (prior sponsor, Abbott)922009-06-012018-06-06
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
atrasentan hydrochloride - Kidney Cancer
Phase 2CompletedEastern Cooperative Oncology Group1802003-07-142023-06-22
Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
atrasentan hydrochloride, doxil - Fallopian Tube Cancer, Ovarian Cancer
Phase 2TerminatedVanderbilt-Ingram Cancer Center152003-05-012012-05-23
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
Atrasentan - Prostatic Neoplasms
Phase 2CompletedAbbott2002002-05-012006-08-15
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
Atrasentan, Zoledronic Acid (Zometa) - Prostate Cancer, Adenocarcinoma of the Prostate
Phase 2CompletedMassachusetts General Hospital442001-12-012010-05-10
A Long Term Safety Study With Atrasentan
Atrasentan - Prostate Cancer, Adenocarcinoma
Phase 2 / Phase 3CompletedAbbott1662001-07-012007-11-29

Conditions studied

Diabetic Nephropathies (6)  ·  Renal Insufficiency, Chronic (5)  ·  Prostatic Neoplasms (3)  ·  Proteinuria (3)  ·  Glomerulonephritis, IGA (2)  ·  Kidney Diseases (2)  ·  Urologic Diseases (2)  ·  Adenocarcinoma (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Carcinoma, Renal Cell (1)  ·  Diabetes Complications (1)  ·  Diabetes Mellitus (1)  ·  Endocrine System Diseases (1)  ·  Fallopian Tube Neoplasms (1)  ·  Glomerulonephritis (1)

Sponsors

AbbVie (prior sponsor, Abbott) (4)  ·  Abbott (2)  ·  Novartis Pharmaceuticals (2)  ·  AbbVie (1)  ·  Eastern Cooperative Oncology Group (1)  ·  Massachusetts General Hospital (1)  ·  Vanderbilt-Ingram Cancer Center (1)

Countries

United States (11)  ·  Canada (3)  ·  Spain (3)  ·  Australia (2)  ·  Italy (2)  ·  Puerto Rico (2)  ·  South Korea (2)  ·  United Kingdom (2)  ·  Brazil (1)  ·  France (1)  ·  Germany (1)  ·  Japan (1)  ·  Malaysia (1)  ·  Netherlands (1)  ·  Taiwan (1)

Top investigators

Blai Coll, MD (2)  ·  Darryl Sleep, M.D. (1)  ·  Dennis Andress (1)  ·  Gary Gordon, MD (1)  ·  Marta Crispens, MD (1)  ·  Matthew Smith, MD, PhD (1)  ·  Michael A. Carducci, MD (1)

Results publications

PMID 28756065, PMID 24722445, PMID 26153128, PMID 33270906, PMID 37254256, PMID 37716952, PMID 38299639, PMID 39899371, PMID 40938675, PMID 41442197, PMID 41904616

NIH funding

2016 (1), 2023 (1)